-
Ibrexafungerp Against Echinocandin-Resistant Candida
2026-09-19
This study evaluated ibrexafungerp against 192 clinically collected Candida isolates with phenotypic or genotypic echinocandin resistance, resolving susceptibility by species and FKS hotspot mutation. Its findings show retained activity in many isolates, but also reveal mutation-position and species-dependent differences that matter for resistance interpretation and translational study design.
-
Exosomal miR-17-5p in Sepsis Lung Injury
2026-09-18
The reference study identifies a plasma extracellular-vesicle miR-17-5p–Bcl11b axis that modulates macrophage polarization and sepsis-associated lung injury. Its combined clinical-sample, cell, animal, transcriptomic, and reporter-assay design provides a useful framework for evaluating extracellular miRNAs as mechanistic biomarkers, while also highlighting an apparent directional inconsistency in the reported conclusion.
-
Linagliptin and the p-Tau Ser356 Question
2026-09-18
A translational framework for positioning Linagliptin (BI-1356) alongside NUAK-focused tau research, using human brain slice evidence to define what is known, what remains unproven, and how to design a disciplined repurposing study.
-
Electrical Stimulation Boosts Nanoparticle Uptake
2026-09-17
The reference study shows that alternating-current electrical stimulation increases magnetic nanoparticle endocytosis in cancer cells, primarily through macropinocytosis associated with F-actin reduction and intracellular Ca2+ elevation. The approach improved magnetic hyperthermia and MRI readouts across multiple cell and nanoparticle types, suggesting a broadly adaptable physical strategy for nanomedicine.
-
FAISL–FAK Proteolysis in Triple-Negative Breast Cancer
2026-09-17
The reference study identifies FAISL as a long noncoding RNA that stabilizes focal adhesion kinase by blocking Calpain 2-mediated proteolysis, thereby promoting triple-negative breast cancer progression and metastasis. Its combination of transcriptomic discovery, mechanistic interaction studies, functional assays, and nanoparticle-based knockdown provides a framework for studying post-translational control of FAK in TNBC.
-
Nicotine Signaling in Chronic Kidney Disease
2026-09-16
Jain and Jaimes synthesize clinical and experimental evidence that nicotine, acting through non-neuronal nicotinic acetylcholine receptors, may accelerate chronic kidney disease through hemodynamic, oxidative, and profibrotic mechanisms. The review’s main practical contribution is a framework for separating nicotine-dependent signaling from the broader toxicology of cigarette smoke when designing kidney disease studies.
-
Cyclic di-GMP Workflows for Biofilm and STING
2026-09-16
Cyclic di-GMP connects bacterial biofilm persistence experiments with mammalian STING activation workflows. This guide translates its antitoxin biology and immune-signaling activity into practical assay design, controls, optimization steps, and troubleshooting strategies.
-
Clodronate Liposomes for In Vivo Macrophage Depletion
2026-09-15
Clodronate Liposomes deliver liposome-encapsulated clodronate to phagocytic macrophages for selective depletion in animal models. The reagent supports route-dependent immune cell modulation, while PBS Liposomes provide an appropriate blank-liposome control.
-
NETs in CML: TKI Effects and Vascular Risk
2026-09-15
The reference study shows that neutrophil extracellular traps (NETs) are elevated in treatment-naive chronic myeloid leukemia and can be differentially modified by tyrosine kinase inhibitors. Its combined human-sample and BCR-ABL1 model design links leukemic signaling to a plausible thrombo-inflammatory mechanism while emphasizing that TKI-associated vascular effects require further clinical validation.
-
Metabolic Sensitization of Ferroptosis and Cuproptosis
2026-09-14
The 2024 Chemical Engineering Journal study presents SCu/L, a copper–tannic acid/liposome nanosystem that combines copper delivery with STF-31-mediated inhibition of glycolysis and NAD+ metabolism. By reducing glucose, NAD+, NADPH, ATP, glutathione synthesis, and copper efflux capacity, the strategy is designed to increase ferroptosis and cuproptosis while improving immunogenic tumor-cell killing.
-
Ibrexafungerp: Applied Antifungal Workflows
2026-09-13
Ibrexafungerp, also known as MK 3118, connects oral glucan-synthase inhibition with practical workflows for resistant Candida research. This guide translates susceptibility testing, acidic-pH assays, and delayed-treatment animal studies into reproducible experimental decisions.
-
Biotin (Vitamin B7) for Motor-Protein Assay Design
2026-09-12
Biotin (Vitamin B7) is more than a metabolic cofactor: it is a versatile assay-design tool for separating molecular capture from motor-protein activation. This guide uses recent BicD–MAP7–kinesin research to explain labeling choices, controls, and interpretation limits.
-
SB-3CT: A Translational Lens on MMP9 Matrix Biology
2026-09-11
SB-3CT is more than a gelatinase inhibitor: it is a mechanistic probe for testing how MMP-2 and MMP-9 reshape extracellular matrices in cancer and neural systems. This article connects recent Adamtsl3–MMP9 findings in perineuronal nets with practical assay design, translational decision points, and the limits of cross-domain interpretation.
-
Rhodamine B for Trypsin-Responsive Assays
2026-09-11
Learn how Rhodamine B can serve as a practical optical reporter for nanoparticle uptake, trigger-responsive release, and cell localization in acute pancreatitis research. This workflow separates particle delivery from cargo release while adding controls for fluorescence-based assay reproducibility.
-
Myeloma Cell-Line Mutations and Drug Resistance
2026-09-10
This study provides a large-scale exome-based map of mutations across human multiple myeloma cell lines and connects recurrent genomic alterations with oncogenic pathways and drug-response phenotypes. Its principal practical value is a framework for selecting genetically informative models and interpreting resistance studies without treating all myeloma cell lines as interchangeable.